Bionano Genomics, Inc.

Bionano Genomics, Inc. is a genome analysis company headquartered in San Diego, California. Its mission is to empower researchers and clinicians with advanced genomic analysis tools to unlock new discoveries and improve patient care, striving to elevate health and wellness for all through its optical genome mapping (OGM) solutions.

The company's core offerings include the Saphyr and Stratys™ optical genome mapping systems, DLS™ reagents, and the Bionano Access™, Bionano Solve™, and VIA™ software suites for data analysis and interpretation. Bionano also provides contract genome mapping services and offers diagnostic testing through its Lineagen business, focusing on conditions like autism spectrum disorder and other neurodevelopmental disabilities. Additionally, its CLIA-certified Bionano Laboratories provides OGM-based laboratory developed tests. These solutions are utilized by academic research institutions, biotechnology and pharmaceutical companies, clinical laboratories, and government agencies for applications in cancer genomics, rare disease diagnostics, and translational research.

Led by CEO Erik Holmlin, Bionano Genomics is positioned as a leader in OGM technology, providing critical tools for detecting structural variants often missed by other genomic methods. The company reported Q4 2025 revenue of $8.0 million and full-year 2025 revenue of $28.5 million, with a gross margin of 46%. Recent studies have demonstrated OGM's superior performance over traditional methods in analyzing conditions like multiple myeloma, and the company continues to see an increase in OGM studies presented at major scientific meetings. Bionano is currently undergoing a strategic transformation to enhance cash efficiency and concentrate on its core OGM business.